Nia Therapeutics is developing first-in-class deep-brain stimulation (DBS) devices to restore memory function in patients with traumatic brain injury and neurodegenerative disease. The prevalence of memory disorders due to injury and disease is over 7M in the US and represents a market of over $3B. Our technology platform was developed at U. Penn with $24M in funding from DARPA and represents the next generation of DBS devices.